Database→MOTS-c

Tier 3–4MetabolicAnti-agingMitochondrialPREMIUM

MOTS-c

Mitochondrial ORF of the 12S rRNA Type-C (MOTS-c)

No regulatory approvals worldwide. Investigational. CB4211 (MOTS-c analog) completed Phase 1a/1b but program discontinued. Not FDA-scheduled. USADA has specifically flagged MOTS-c as a substance of concern given exercise-mimicking properties. Verify WADA status annually.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use

Profile Overview

MOTS-c is the only peptide in this research series encoded by mitochondrial (not nuclear) DNA. A mitochondrial-derived 16-amino acid peptide discovered in 2015, it functions as an exercise-induced signaling molecule that activates AMPK via the folate-methionine cycle. Its CB4211 analog completed a Phase 1b NAFLD trial showing significant liver enzyme and glucose improvement. No human therapeutic trials for MOTS-c itself exist.

🔒

Full Profile: Premium Members Only

The complete MOTS-c profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.

For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use